A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
Conditions:   Dyslipidemias;   Non-Alcoholic Fatty Liver Disease Interventions:   Drug: LY3885125;   Drug: Placebo Sponsor:   Eli Lilly and Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials